MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2. These include recent presentations at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the American College of Clinical Pharmacology (ACCP) and upcoming presentations at the Infectious Diseases Society of America (IDSA) annual meeting.
